GRI BIO, Inc. and Vallon Pharmaceuticals, Inc. have entered into a merger agreement, and Vallon has received demands from stockholders alleging misleading information in the prospectus, prompting Vallon to voluntarily supplement the prospectus to avoid potential litigation.